(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial - 2The 2026 'Super Bowl of Astronomy' starts today — here's what's happening
- 3Jamaica reports deadly leptospirosis outbreak after Hurricane Melissa
- 4Extraordinary Shows to Long distance race on a Plane
- 5How to watch the ‘Wicked: One Wonderful Night’ special — now streaming
- 5 Most Expected Film Delivery
- Was This Driver Simply Having Some good times Or Behaving Like An Ass?
- Who is Adm. Frank 'Mitch' Bradley and what does he have to do with the Venezuela boat strikes?
- Find Wonderful Stream Voyage Objections On the planet
- Israeli archaeologists launch project to trace origins of ancient pottery
- Key Caper d: A Survey of \Procedure and Tomfoolery Released\ Tabletop game
- Pick Your Favored pizza beating
- 10 Asian Countries Perfect for Solo Female Travelers
- The Force of Organic product: 10 Assortments That Improve Your Wellbeing
